Regular Article

British Journal of Cancer (2001) 84, 11–16. doi:10.1054/bjoc.2001.1747 www.bjcancer.com
Published online 3 April 2001

Pharmacokinetics of novel erythropoiesis stimulating protein (NESP) in cancer patients: preliminary report

A C Heatherington1, J Schuller2 and A J Mercer3

  1. 1Amgen Inc, One Amgen Center Drive, Thousand Oaks, CA, 91320–1799, USA
  2. 2Krankenanstalt Rudolstiftung, Medizinische Abteilung – Onkologie, Juchgasse 25, Vienna 1030, Austria
  3. 3Amgen Ltd, Milton Road, Cambridge CB4 OWD, UK
Top

Abstract

Anaemia is a common occurrence in patients with cancer, and currently can be treated in several ways. Novel erythropoiesis stimulating protein (NESP, darbepoetin alfa) was created using site-directed mutagenesis to have 8 more sialic acid side chains than recombinant human erythropoietin (rHuEPO). The additional sialic acid content has resulted in an approximately 3-fold greater half-life relative to rHuEPO in patients with chronic renal failure. This study evaluates the pharmacokinetic profile of NESP in patients receiving multiple cycles of chemotherapy. Anaemic patients (haemoglobin less than or equal to 11.0 g dl–1) who had non-myeloid malignancies received NESP weekly (2.25 mcg kg–1 wk–1) under the supervision of a physician, starting on day 1 of chemotherapy for 3 chemotherapy cycles given at 3-week intervals. Blood samples were collected during chemotherapy cycles 1 and 3 for pharmacokinetic analysis. All patients were followed for 4 weeks after treatment. NESP was well tolerated by all patients. After a single dose during chemotherapy cycle 1, pharmacokinetic parameters (mean (SD), n) for the first 15 patients were: Tmax86.1 (22.8) h (n = 14); Cmax9.0 (5.1) ng ml–1(n = 14); t1/2,z32.6 (11.8) h (n = 7); CL/F 3.7 (1.0) ml h–1 kg–1(n = 7). The subjects for whom all parameters could be calculated may represent a sub-group of the entire population. Similar results were obtained in cycle 3. In addition, haemoglobin response data suggests that, in this patient population, dosing less frequently than the 3 times weekly doses used for rHuEPO may be possible while improving anaemia. © 2001 Cancer Research Campaign

Keywords:

cancer, chemotherapy, clinical study, darbepoetin alfa, pharmacokinetics

Top

References

  1. Cascinu S, Fedeli A, Del Ferro E, Luzi Fedeli S and Catalano G (1994) Recombinant human erythropoietin treatment in cisplatin-associated anemia: a randomized double-blind trial with placebo. J Clin Oncol 12: 1058–1062 | PubMed | ISI | ChemPort |
  2. Del Mastro L, Venturini M, Lionetto R, Garrone O, Melioli G, Pasquetti W, Sertoli MR, Bertelli G, Canavese G, Costantini M and Rosso R (1997) Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia. J Clin Oncol 15: 2715–2721 | PubMed | ChemPort |
  3. Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S and Vadhan RS (1997) Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 15: 1218–1234 | PubMed | ISI | ChemPort |
  4. Glaspy J, Colowick AB and Heatherington A (2000) Novel erythropoiesis stimulating protein (NESP) exhibits a prolonged serum half-life (T1/2) in oncology patients (pts). Proc Am Soc Clin Oncol 19: 54a (abstract 210)
  5. Glaspy J, Jadeja JS, Justice G, Kessler J, Richards D, Schwartzberg L, Rigas J, Kuter D, Harmon D, Prow D, Demetri G, Gordon D, Arseneau J, Saven A, Hynes H, Boccia R, O'Byrne J and Colowick AB (2001) A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy. Br J Cancer 84: 17–23 | Article |
  6. Henry DH (1998) Epoetin alfa and high-dose chemotherapy. Semin Oncol 25: 54–57 | PubMed | ISI | ChemPort |
  7. Henry DH and Abels RI (1994) Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: Results of double-blind and open-label follow-up studies. Semin Oncol 21: 21–28 | PubMed | ISI | ChemPort |
  8. Ludwig H, Sundal E, Pecherstorfer M, Leitgeb C, Bauernhofer T, Beinhauer A, Samonigg H, Kappeler AW and Fritz E (1995) Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy. Cancer 76: 2319–2329 | PubMed | ISI | ChemPort |
  9. Macdougall IC (2000) Novel erythropoiesis stimulating protein. Semin Nephrol 20: 375–381 | PubMed | ISI | ChemPort |
  10. Macdougall IC, Roberts DE, Neubert P, Dharmasena AD, Coles GA and Williams JD (1989) Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Lancet 1: 425–427 | Article | PubMed | ISI | ChemPort |
  11. Macdougall IC, Gray S, Elston O, Breen C, Jenkins B, Browne J and Egrie J (1999) Pharmacokinetics of novel erythropoiesis stimulating protein compared with Epoetin alfa in dialysis patients. J Am Soc Nephrol 10: 2392–2395 | PubMed | ISI | ChemPort |
  12. Maraveya S and Pettengell R (1998) What is the role of erythropoietin in patients with solid tumours?. Ann Oncol 9: 239–241 | Article | PubMed |
  13. Miller CB, Platanias LC, Mills SR, Zahurak ML, Ratain MJ, Ettinger DS and Jones RJ (1992) Phase I–II trial of erythropoietin in the treatment of cisplatin-associated anemia. J Natl Cancer Inst 84: 98–103 | Article | PubMed | ChemPort |
  14. Piroso E, Erslev AJ and Caro J (1989) Inappropriate increase in erythropoietin titers during chemotherapy. Am J Hematol 32: 248–254 | PubMed | ISI | ChemPort |
  15. Platanias LC, Miller CB, Mick R, Hart RD, Ozer H, McEvilly JM, Jones RJ and Ratain MJ (1991) Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients. J Clin Oncol 9: 2021–2026 | PubMed | ISI | ChemPort |
  16. Sawabe Y, Kikuno K, Iseki T, Iida S, Tabata Y and Yonemitsu H (1996) Changes in serum erythropoietin and the reticulocyte count during chemotherapy for leukemias. Eur J Haematol 57: 384–388 | PubMed | ISI | ChemPort |
  17. Spivak JL and Hogans BB (1989) The in vivo metabolism of recombinant human erythropoeitin in the rat. Blood 73: 90–99 | PubMed | ISI | ChemPort |